A WIRED investigation has documented a pattern of consumer fraud by online telehealth company FitRx, operating as Zealthy Inc., in which patients are charged hundreds of dollars for GLP-1 weight-loss drugs they never ordered and then denied refunds using 'supply chain' and 'privacy' pretexts. The report underscores growing compliance and logistical risks in a sector forecast to hit $150 billion within five years.
The Scale of Online GLP-1 Fraud
According to WIRED, one in eight American adults now takes GLP-1 drugs, and 11 percent of them obtained prescriptions through online telehealth services — a segment experiencing 24 percent annual growth. Forecasters predict the online weight-loss drug market will reach $150 billion within five years. The U.S. government itself entered the space with the recent TrumpRx program. However, not all providers operate in good faith, as demonstrated by FitRx/Zealthy.
John Semley, a WIRED journalist, detailed his own experience: In March 2026, he signed up for FitRx expecting a $135 monthly supply of compounded Zepbound (tirzepatide). Instead, he was charged $866 and sent a three-month supply of vials he did not request. No attempt was made to check insurance coverage. When he tried to cancel, the company refused, citing a policy of no refunds after shipping labels are printed. The shipper, FedEx, confirmed it could have canceled the shipment, but FitRx/Zealthy did not.
How the Scheme Operates
WIRED documented multiple victims with similar stories. Shane Albert (a pseudonym) reported that after a smooth initial order, Zealthy charged him higher prices for a dose increase and delivered weeks late. He could not remove his credit card from the website and had to order a new card. Nicole Butler received a three-month Zepbound supply left in the North Carolina summer heat, melting the cooler bags and potentially spoiling the drug. Zealthy refused a refund despite her complaints to JAMS and her credit card issuer. Sarah Harris claimed she was bilked for more than $1,500, receiving tracking numbers for shipments that never arrived. She ultimately had to order a new debit card to stop recurring charges.
| Customer | Amount Charged | Product | Issue | Outcome |
|---|---|---|---|---|
| John Semley | $866 | Tirzepatide vials (3-month supply) | Unwanted shipment after $135 sign-up | Refund denied; shipment refused and returned to sender |
| Shane Albert | Increased dose cost | Tirzepatide | Late delivery, price hike, unable to remove card | Had to order new credit card |
| Nicole Butler | Not specified | Zepbound (3-month supply) | Delivery left in heat, drug potentially spoiled | Refund refused; charge investigation initiated |
| Sarah Harris | Over $1,500 | Semaglutide/tirzepatide | Tracking numbers for undelivered orders; cancellation blocked | Cancelled debit card |
Supply Chain and Logistics Implications
For trade and logistics professionals, the Zealthy case highlights weaknesses in pharmaceutical supply chain controls. The company ships from an intermediary pharmacy in Texas via FedEx, and uses a policy that orders cannot be canceled or returned after label printing — a claim FedEx disputes. WIRED found that FedEx can cancel shipments before dispatch. This 'label-printing' loophole allows companies like Zealthy to block refunds while preserving the ability to ship unwanted products.
Additionally, the lack of temperature control during last-mile delivery poses spoilage risks for biologics like tirzepatide, which require cold chain integrity. Butler's shipment left in the sun is a clear breach of good distribution practices. Importers and freight forwarders handling pharmaceutical cold chain shipments should note that such incidents could lead to regulatory scrutiny.
Regulatory Scrutiny and Response
In 2024, the U.S. Department of Justice and the Federal Trade Commission announced a crackdown on deceptive online telehealth practices, though Zealthy's specific case was not cited. CEO Kyle Robertson, a Wharton School dropout, declined to comment when confronted by WIRED at the company's Manhattan office, telling the journalist to 'please leave.' Customer service representatives, including one who identified only as 'Jojie,' promised follow-up that never came. Zealthy's legal representatives also did not respond to repeated requests.
For trade policy analysts, the case underscores the need for stricter enforcement of Federal Trade Commission rules against deceptive billing and for U.S. Food and Drug Administration oversight of compounded GLP-1 drugs shipped across state lines. The growth of online pharmacies, especially with government programs like TrumpRx, will demand clearer customs and postal regulations for prescription drugs.
What to watch: Whether the FTC or DOJ takes enforcement action against FitRx/Zealthy, and whether Congress or regulators introduce new labeling and cancellation transparency requirements for online pharmaceutical shipments.
Sources:
